179 related articles for article (PubMed ID: 18675099)
1. The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series.
Viganò J; Gruttadauria S; Mandalà L; Petridis I; Cintorino D; Li Petri S; Varotti G; Minervini M; Volpes R; Biondo D; Vizzini G; Marsh WJ; Marcos A; Gridelli B
Transplant Proc; 2008; 40(6):1953-5. PubMed ID: 18675099
[TBL] [Abstract][Full Text] [Related]
2. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation.
Gruttadauria S; Vasta F; Mandalà L; Cintorino D; Piazza T; Spada M; Verzaro R; Gridelli B
Transplant Proc; 2005; 37(6):2611-3. PubMed ID: 16182762
[TBL] [Abstract][Full Text] [Related]
3. A safe immunosuppressive protocol in adult-to-adult living related liver transplantation.
Gruttadauria S; Cintorino D; Piazza T; Mandala L; Doffria E; Musumeci A; Di Trapani G; Arcadipane A; Scianna G; Spada M; Verzaro R; Volpes R; Vizzini G; Palazzo U; Minervini M; Marsh JW; Marcos A; Gridelli B
Transplant Proc; 2006 May; 38(4):1106-8. PubMed ID: 16757278
[TBL] [Abstract][Full Text] [Related]
4. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months.
Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
Transplant Proc; 2006 Dec; 38(10):3633-5. PubMed ID: 17175352
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients.
Marino IR; Doria C; Scott VL; Foglieni CS; Lauro A; Piazza T; Cintorino D; Gruttadauria S
Transplantation; 2004 Sep; 78(6):886-91. PubMed ID: 15385809
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
[TBL] [Abstract][Full Text] [Related]
7. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation.
Lin CC; Chuang FR; Lee CH; Wang CC; Chen YS; Liu YW; Jawan B; Chen CL
Liver Transpl; 2005 Oct; 11(10):1258-64. PubMed ID: 16184544
[TBL] [Abstract][Full Text] [Related]
8. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
[TBL] [Abstract][Full Text] [Related]
10. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes.
Humar A; Crotteau S; Gruessner A; Kandaswamy R; Gruessner R; Payne W; Lake J
Clin Transplant; 2007; 21(4):526-31. PubMed ID: 17645714
[TBL] [Abstract][Full Text] [Related]
11. Role of basiliximab in the prevention of acute cellular rejection in adult to adult living-related liver transplantation: a single center experience.
Gruttadauria S; Mandalà L; Biondo D; Spampinato M; Lamonaca V; Volpes R; Vizzini G; Marsh J; Marcos A; Gridelli B
Biologics; 2007 Mar; 1(1):69-73. PubMed ID: 19707350
[TBL] [Abstract][Full Text] [Related]
12. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.
Neuhaus P; Clavien PA; Kittur D; Salizzoni M; Rimola A; Abeywickrama K; Ortmann E; Chodoff L; Hall M; Korn A; Nashan B;
Liver Transpl; 2002 Feb; 8(2):132-42. PubMed ID: 11862589
[TBL] [Abstract][Full Text] [Related]
13. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
14. Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants.
Hoshinaga K; Aikawa A; Murai M; Yamamoto H; Hirayama N; Shishido S; Hasegawa A
Transplant Proc; 2005 May; 37(4):1762-3. PubMed ID: 15919457
[TBL] [Abstract][Full Text] [Related]
15. Routine induction therapy in living donor liver transplantation prevents rejection but may promote recurrence of hepatitis C.
Ghanekar A; Kashfi A; Cattral M; Selzner N; McGilvray I; Selzner M; Renner E; Lilly L; Levy G; Grant D; Greig P
Transplant Proc; 2012 Jun; 44(5):1351-6. PubMed ID: 22664014
[TBL] [Abstract][Full Text] [Related]
16. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
Liu CL; Fan ST; Lo CM; Chan SC; Ng IO; Lai CL; Wong J
Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
[TBL] [Abstract][Full Text] [Related]
19. Steroid-free liver transplantation in children.
Reding R; Gras J; Sokal E; Otte JB; Davies HF
Lancet; 2003 Dec; 362(9401):2068-70. PubMed ID: 14697809
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients.
Ganschow R; Grabhorn E; Schulz A; Von Hugo A; Rogiers X; Burdelski M
Pediatr Transplant; 2005 Dec; 9(6):741-5. PubMed ID: 16269045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
